Panitumumab and Irinotecan for Malignant Gliomas

NCT01017653 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped study did not reach benchmark efficacy rule at 16 subjects

Conditions

Malignant Glioma of Brain

Interventions

DRUG: Irinotecan
DRUG: Panitumumab

Sponsor

Annick Desjardins

Collaborators

[object Object]